Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Total Current Liabilities
All obligations due within one year.
Upstream Bio, Inc.NASDAQ: UPB
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 42.9% from a year ago
Total current liabilities stood at $13.67M at the end of Q1 FY2026, up 42.9% from a year earlier and up 1.6% from the prior quarter. Over 3 fiscal years it compounded at +40.4% a year.
Context
- Total current liabilities amounted to 4.3% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +42.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 13.45M USD
- Year-over-year change
- +25.3%
- 3-year CAGR
- +40.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.45M | +25.3% |
| FY2024 | 2024-12-31 | 10.74M | +64.8% |
| FY2023 | 2023-12-31 | 6.52M | +34.2% |
| FY2022 | 2022-12-31 | 4.86M | — |
Total Current Liabilities vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +42.9% is the 2nd highest of 10, against a peer median of -8.9%.
- Total current liabilities amounts to 4.3% of total assets for UPB, versus a peer median of 8.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $342.46M USD | -18.9% | -42.8% | 32.8% | |
| Mar 2026 | $86.17M USD | -8.9% | +60.5% | 18.2% | |
| Mar 2026 | $76.45M USD | -32.1% | -6.4% | 10.1% | |
| Mar 2026 | $61.16M USD | +24.5% | +34.1% | 8.2% | |
| Jun 2026 | $50.8M USD | +56.2% | -26.2% | 5.3% | |
| Mar 2026 | $49.83M USD | -43.0% | +10.0% | 8.5% | |
| Sep 2026 | $40.14M USD | -13.2% | +58.8% | 3.7% | |
| Sep 2026 | €29.66M EUR | +13.1% | +17.6% | 10.1% | |
| Sep 2026 | $29.05M USD | +12.6% | -21.3% | 3.7% | |
UPBUpstream Bio, Inc. | Mar 2026 | $13.67M USD | +42.9% | +40.4% | 4.3% |
| Peer median (excluding UPB) | — | -8.9% | +10.0% | 8.5% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.